Alpha1-Antitrypsin Deficiency Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis
In some people, the liver makes an abnormal version of the alpha-1 antitrypsin (AAT) protein, called Z-AAT. Making an abnormal version of the AAT protein can result in liver disease as Z-AAT builds up in liver cells, which leads to liver problems such as liver scarring (fibrosis), continuing liver damage (cirrhosis), and eventually endstage liver disease. Fazirsiran is a medicine that reduces the creation of the Z-AAT protein and thus the build-up of this abnormal protein in the liver. People with this type of liver disease who already have mild liver scarring will take part in the study. They will be treated with fazirsiran or a placebo for about 2 years. This study will check the long-term safety of fazirsiran and if participants tolerate the treatment. A liver biopsy, a way of collecting a small tissue sample from the liver, will be taken twice during the study.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02282527 -
A Study to Assess Safety and PK of Liquid Alpha1-Proteinase Inhibitor (Human) in Treating Alpha1-Antitrypsin Deficiency
|
Phase 2/Phase 3 | |
| Terminated |
NCT02722304 -
Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency
|
Phase 3 | |
| Withdrawn |
NCT04440488 -
ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study
|
Phase 4 | |
| Completed |
NCT02525861 -
GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study
|
Phase 3 | |
| Recruiting |
NCT05677971 -
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
|
Phase 3 | |
| Completed |
NCT00157092 -
Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency
|
Phase 1/Phase 2 | |
| Terminated |
NCT00313144 -
Aralast alpha1-proteinase Inhibitor Surveillance Study
|
Phase 4 | |
| Completed |
NCT01651351 -
GLASSIA Infusion Rate Study
|
Phase 4 | |
| Completed |
NCT02870309 -
Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin Deficiency
|
Phase 1/Phase 2 | |
| Completed |
NCT02870348 -
Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE)
|
Phase 1/Phase 2 | |
| Completed |
NCT04474197 -
Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype
|
Phase 2 | |
| Completed |
NCT00161707 -
Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT05466747 -
A Study of RYMPHYSIA for Alpha1-Proteinase Inhibitor (A1PI) Therapy in Adults With A1PI Deficiency and Chronic Obstructive Pulmonary Disease (COPD)-Emphysema
|
Phase 4 | |
| Enrolling by invitation |
NCT05899673 -
An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease
|
Phase 3 | |
| Recruiting |
NCT04722887 -
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02929940 -
Liver Disease in Patients With alpha1-antitrypsin Deficiency
|
N/A |